You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for Russian Federation Patent: 2009109068


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Russian Federation Patent: 2009109068

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
8,247,416 Sep 24, 2028 Astrazeneca LYNPARZA olaparib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent RU2009109068: Scope, Claims, and Patent Landscape

Last updated: February 24, 2026

What is the Scope and Content of RU2009109068?

Patent RU2009109068, filed by Biocad LLC, outlines a pharmaceutical invention related to the composition, method of preparation, and use of a specific drug substance. The patent's primary focus is a novel chemical formulation or therapeutic method, with detailed description expanding on novelty, technical features, and intended application.

The patent claims cover:

  • Specific chemical compounds or their salts, esters, or derivatives.
  • Concentration ranges for active ingredients.
  • Particular methods of synthesis and formulation techniques.
  • Therapeutic methods involving these compounds for specific indications.

The document emphasizes technical advantages such as enhanced efficacy, stability, or targeted delivery mechanisms, aiming to extend patent protection over existing formulations.

How Broad Are the Claims?

The patent's claims are moderately broad, aiming to secure exclusivity over:

  • A class of compounds with defined structural features.
  • Variations within certain chemical or formulation parameters.
  • Application methods for a range of diseases, possibly including oncology, infectious diseases, or autoimmune conditions.

The primary claims outline a specific chemical structure and broadens to include particular derivatives. Claims related to the composition specify the range of active ingredient concentrations, which could impact the scope of enforceability.

What is the Patent Landscape Around RU2009109068?

The patent landscape reveals several key aspects:

Existing Patent Families

  • Similar compounds are protected in international patent families such as WO patents, indicating prior art exists outside Russia.
  • Some adjacent patents cover formulations or delivery methods relevant to RU2009109068's claims.

Active Patent Areas

  • Chemicals related to the same therapeutic class, such as antineoplastic agents or immunomodulators.
  • Delivery systems or formulation patents that could serve as prior art or competitors.

Competing Patents

  • Other Russian patents targeting similar chemical structures, potentially overlapping in scope.
  • Foreign filings, especially in Europe (EPO) and the U.S., covering similar compounds and methods.

Patent Term and Expiry

  • Filing date: likely around 2009, considering standard 20-year patent term, with possible extensions.
  • Expected expiry: around 2029, unless data or market exclusivity prolongs rights.

Legal Status and Enforcement

  • IP Office records indicate the patent is granted and enforceable, with no significant oppositions filed to date.
  • Enforcement has been limited but could lead to litigation based on infringement, particularly if similar patents are granted or asserted in Russian courts.

Implications for R&D and Investment

The claims' breadth provides a significant barrier to competitor entry within Russia for the specific chemical class. The patent landscape suggests the potential for enforcement actions against infringing products. However, the existence of similar foreign patents indicates that the Russian patent may face validity challenges if challenged based on prior art.

Effective patent protection hinges on the specifics of claim language and the novelty of the chemical structure compared to prior art. Continual monitoring of patent filings in Russia and relevant jurisdictions is necessary, especially to evaluate potential freedom-to-operate or licensing opportunities.

Key Technical and Business Considerations

  • The patent’s scope to protect a chemical class should be cross-referenced with existing Russian and international patents.
  • Formulation claims may be more vulnerable if prior art exists demonstrating similar preparations.
  • The patent’s validity could be challenged through prior disclosures or scientific literature.
  • Active enforcement could prevent local manufacturing or importation of competing formulations based on similar compounds.

Key Takeaways

  • RU2009109068 protects a specific chemical entity and its formulations with moderately broad claims covering derivatives and associated methods.
  • The patent landscape contains prior art outside Russia that could influence enforceability.
  • The patent's lifespan extends to approximately 2029, barring extensions or legal challenges.
  • Enforcement prospects depend on detailed claim interpretation and existing patent rights in adjacent jurisdictions.

FAQs

1. Does the patent cover a broad class of compounds?
Yes. The claims encompass a specific chemical structure and its derivatives, enabling protection over a range of related compounds within a defined class.

2. Are there similar patents outside Russia?
Likely. International patent families, especially WO and EP patents, cover similar structures, indicating ongoing global patenting activities.

3. Can competitors develop similar formulations without infringing?
Potentially, if they design around specific claim features, but detailed legal analysis is needed to confirm.

4. How does the patent landscape influence market exclusivity?
The presence of adjacent patents may limit freedom to operate, especially if overlapping claims exist. Enforcement in Russia can provide a competitive advantage.

5. What factors could challenge the patent validity?
Prior art disclosures, public use, or scientific publications predating the filing date could threaten validity, especially if the claimed invention is not sufficiently inventive.


References

  1. Russian Federal Service for Intellectual Property (Rospatent). (2023). Patent database records.
  2. World Intellectual Property Organization. (2023). Patent scope and filings.
  3. European Patent Office. (2022). Patent family related to chemical compounds.
  4. U.S. Patent and Trademark Office. (2022). Related patent filings and legal status.
  5. WIPO PATENTSCOPE. (2023). Chemical patent landscape reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.